Traitement du SARS-CoV-2 en pédiatrie : quelles évidences et quelle utilité ? [Treatment of SARS-CoV-2 in paediatrics : what is the evidence to date?]
Fiche du document
17 février 2021
- doi: 10.53738/REVMED.2021.17.726.0344
- issn: 1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.53738/REVMED.2021.17.726.0344
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/33599410
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pissn/1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_9FD582ADE3EC3
info:eu-repo/semantics/openAccess , CC BY-NC-ND 4.0 , https://creativecommons.org/licenses/by-nc-nd/4.0/
Sujets proches
Pediatric medicine PaediatricsCiter ce document
Y. Fougère et al., « Traitement du SARS-CoV-2 en pédiatrie : quelles évidences et quelle utilité ? [Treatment of SARS-CoV-2 in paediatrics : what is the evidence to date?] », Serveur académique Lausannois, ID : 10.53738/REVMED.2021.17.726.0344
Métriques
Partage / Export
Résumé
Although SARS-CoV-2 infects individuals of all ages, children show less severe symptoms. Nevertheless, the very rare COVID-19 severe cases in paediatrics require our full attention. Much research has been conducted and is still ongoing on effective treatments. On the antiviral front, no molecule has been proven effective yet and the results of several studies on the benefit of monoclonal antibodies and convalescent plasma are pending. On the side of immunomodulators, the benefit of steroids has been demonstrated for patients severely ill. Other molecules are being investigated. However, all these studies focused on adults and paediatric data are warranted.